Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764 Year All20242023202220212020201920182017201620152014 February 11, 2019 Apellis Pharmaceuticals’ APL-2 Receives Fast Track Designation from the FDA for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria February 5, 2019 Apellis’ APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of Autoimmune Hemolytic Anemia January 31, 2019 Apellis Pharmaceuticals Appoints Thomas Lackner as Senior Vice President, Head of Europe January 2, 2019 Apellis Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference